SILVER SPRING
Afrezza cleared for pediatric diabetes
- Sponsor
- MannKind Corporation $MNKD
- Drug
- Afrezza · insulin human
- Indication
- diabetes
FDA approved inhaled insulin Afrezza for children and adolescents aged 6+ with diabetes.
What this means
Afrezza is an inhaled insulin powder that works faster than traditional insulin shots by absorbing quickly through the lungs. Today FDA expanded its approval to include children and adolescents aged 6 and older with diabetes. This decision could offer younger patients a needle-free insulin option that may fit better into their daily routines.
Drug Watch — recent news on Afrezza
- Myxredlin Market Report Offers Insights on Market Development and Future Growth Opportunities - openPR.com
- Insulin human/insulin isophane human out-of-pocket cost in the U.S. from 2014 to 2023 - Statista
- Top Insulin Brands for Diabetes in Pakistan – Complete Guide 2025 - Bloom Pakistan
- MERP Annual Review Exposes How Manufacturer Labeling/Quality Issues Impact Medication Safety - ECRI
- Diabetes management: Cipla bags CDSCO regulatory nod for distribution, marketing of Afrezza (insulin... - Medical Dialogues
Sponsor Watch — recent news on MannKind Corporation
- Eli Lilly (LLY) Stock Fair Value Edges Higher As Analysts Back GLP 1 Growth
- A drugmaker is gaining from the side effects of weight-loss drugs
- Pfizer to Share Revenue With HHS in Deal on Overseas Drug Prices
- How to position for the next wave of AI-led scientific breakthroughs
- What About the Energy Sector?